AI Biotech Enveda Doubles in Value to $2 Billion

Covered by 2 sources
Read the full article
Enveda Biosciences, supported by a former Johnson & Johnson CEO, has doubled its valuation to $2 billion as it prepares to advance its drug candidates into late-stage clinical trials.

Covered by 2 sources


More in Healthcare

Healthcare2 min read

Google launches $180 Fitbit Edge with a bigger screen and AI coach

The Next Web
Healthcare5 min read

As US medical debt grows, AI will be used more to collect it

The Guardian
Healthcare5 min read

Healthcare AI's Pilot-To-Production Problem

Forbes